-
Je něco špatně v tomto záznamu ?
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
L. Incorvaia, FSM. Monteiro, F. Massari, SH. Park, G. Roviello, O. Fiala, ZW. Myint, J. Kucharz, J. Molina-Cerrillo, D. Santini, T. Buttner, A. Poprach, J. Kopecky, A. Zeppellini, M. Pichler, T. Buchler, R. Pichler, G. Facchini, AP. Fay, A....
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
NLK
Directory of Open Access Journals
od 2024
PubMed Central
od 1982
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-04-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
Springer Journals Complete - Open Access
od 2024-01-01
Springer Nature OA/Free Journals
od 2024-01-01
- MeSH
- dospělí MeSH
- imunoterapie metody MeSH
- inhibitory kontrolních bodů terapeutické užití MeSH
- karcinom z renálních buněk * mortalita imunologie farmakoterapie patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádory ledvin * mortalita imunologie farmakoterapie patologie MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sexuální faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
BACKGROUND: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. METHOD: This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. RESULTS: A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). CONCLUSIONS: Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
Clinical Oncology Sociedad de Oncología Y Hematología del Cesar Valledupar Colombia
Department of Health Sciences University of Florence Florence Italy
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Medical Oncology University Hospital Ramón y Cajal Madrid Spain
Department of Medicine and Surgery University of Parma Via Gramsci 14 43126 Parma Italy
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn 53127 Bonn Germany
Division of Oncology Department of Internal Medicine Medical University of Graz 8036 Graz Austria
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Latin American Cooperative Oncology Group LACOG Porto Alegre RS Brazil
Markey Cancer Center University of Kentucky Lexington KY 40536 0293 USA
Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Bologna Italy
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
National Cancer Centre Singapore Singapore Republic of Singapore
Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda Milan Italy
Oncology and Hematology Center of Hospital Albert Einstein Hospital Albert Einstein Sao Paulo Brazil
Oncology and Hematology Department Hospital Sírio Libanês Brasilia DF Brazil
Oncology Division Hospital 'Maria SS Dello Splendore' ASL 4 Giulianova Italy
Oncology Unit Macerata Hospital Macerata Italy
Oncology Unit S Maria Delle Grazie Hospital ASL NA2 NORD 80078 Pozzuoli Naples Italy
Oncology Unit University Hospital of Parma Via Gramsci 14 43126 Parma Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013574
- 003
- CZ-PrNML
- 005
- 20240905133335.0
- 007
- ta
- 008
- 240725s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-024-03719-0 $2 doi
- 035 __
- $a (PubMed)38832989
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Incorvaia, Lorena $u Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, 90127, Palermo, Italy. lorena.incorvaia@unipa.it
- 245 10
- $a Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations / $c L. Incorvaia, FSM. Monteiro, F. Massari, SH. Park, G. Roviello, O. Fiala, ZW. Myint, J. Kucharz, J. Molina-Cerrillo, D. Santini, T. Buttner, A. Poprach, J. Kopecky, A. Zeppellini, M. Pichler, T. Buchler, R. Pichler, G. Facchini, AP. Fay, A. Soares, R. Manneh, L. Iezzi, Z. Kuronya, A. Russo, MT. Bourlon, D. Bhuva, J. Ansari, R. Kanesvaran, E. Grande, S. Buti, M. Santoni
- 520 9_
- $a BACKGROUND: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. METHOD: This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. RESULTS: A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). CONCLUSIONS: Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x mortalita $x imunologie $x farmakoterapie $x patologie $7 D002292
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory ledvin $x mortalita $x imunologie $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Monteiro, Fernando Sabino Marques $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil. fsabinocba@gmail.com $u Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil. fsabinocba@gmail.com
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
- 700 1_
- $a Park, Se Hoon $u Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea
- 700 1_
- $a Roviello, Giandomenico $u Department of Health Sciences, University of Florence, Florence, Italy
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Alej Svobody 80, Pilsen, 304 60, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, Pilsen, Czech Republic
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, University Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Santini, Daniele $u Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University, Polo Pontino, Rome, Italy
- 700 1_
- $a Buttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Zeppellini, Annalisa $u Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036, Graz, Austria
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a Facchini, Gaetano $u Oncology Unit, "S. Maria Delle Grazie" Hospital, ASL NA2 NORD, 80078, Pozzuoli, Naples, Italy
- 700 1_
- $a Fay, Andre Poisl $u PUCRS School of Medicine, Porto Alegre, RS, Brazil
- 700 1_
- $a Soares, Andrey $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil $u Oncology and Hematology Center of Hospital Albert Einstein, Hospital Albert Einstein, Sao Paulo, Brazil
- 700 1_
- $a Manneh, Ray $u Clinical Oncology, Sociedad de Oncología Y Hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Iezzi, Laura $u Oncology Division, Hospital 'Maria SS. Dello Splendore' ASL 4, Giulianova, Italy
- 700 1_
- $a Kuronya, Zsofia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Russo, Antonio $u Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, 90127, Palermo, Italy
- 700 1_
- $a Bourlon, Maria T $u Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Kanesvaran, Ravindran $u National Cancer Centre Singapore, Singapore, Republic of Singapore
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Buti, Sebastiano $u Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy $u Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy
- 700 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 773 0_
- $w MED00001041 $t Cancer immunology and immunotherapy $x 1432-0851 $g Roč. 73, č. 8 (2024), s. 142
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38832989 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133329 $b ABA008
- 999 __
- $a ok $b bmc $g 2143400 $s 1225440
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 8 $d 142 $e 20240604 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- LZP __
- $a Pubmed-20240725
